Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:14:26 14/05/2024 am IST			5-day change	1st Jan Change
0.0473 ^USD	-7.25%		-63.62%	-94.44%

12:00am	Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P Global BMI Index	CI
12:00am	Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P TMI Index	CI

Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 27, 2023 at 04:58 pm IST

Vaxxinity, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 75.22 million compared to USD 137.18 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 1.79 a year ago.

Latest news about Vaxxinity, Inc.

Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P Global BMI Index	13/05/2024	CI
Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P TMI Index	13/05/2024	CI
Vaxxinity, Inc.(OTCPK:VAXX) dropped from NASDAQ Composite Index	08/05	CI
Sector Update: Health Care Stocks Advance Premarket Monday	22/04	MT
Sector Update: Health Care	22/04	MT
Vaxxinity to Voluntarily Delist From Nasdaq; Shares Sink After Hours	20/04	MT
Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
North American Morning Briefing : Tech in Focus on -2-	25/03	DJ
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson?s Disease at AD/PD? 2024	07/03	CI
Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies	15/02	CI
Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	13/02	CI
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	30/01	CI
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida	18/01	CI
Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors	01/12	CI
Researchers return to Alzheimer's vaccines, buoyed by recent drug success	20/11	RE
Vaxxinity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Vaxxinity, Inc. Announces Executive Changes	29/23/29	CI
Vaxxinity, Inc.(OTCPK:VAXX) added to S&P Global BMI Index	18/23/18	CI
Baird Starts Vaxxinity With Outperform Rating, Price Target is $7	08/23/08	MT
Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease	10/23/10	CI
Vaxxinity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Vaxxinity, Inc. Announces Executive Changes	28/23/28	CI
Vaxxinity Says B-312 Phase 1 Trial Shows Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients; Shares Rise	17/23/17	MT
Vaxxinity, Inc. Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients	17/23/17	CI
Vaxxinity Reports 'Positive' Results in Early-Stage Parkinson's Disease Trial	22/23/22	MT

Chart Vaxxinity, Inc.

Duration

Period

More charts

Company Profile

Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimerâs disease (AD) and UB-312, which targets the pathological process of Parkinsonâs disease (PD) and other so-called synucleinopathies.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
VAXXINITY, INC.	-94.44%	64.64L
MODERNA, INC.	+26.98%	4.5TCr
IQVIA HOLDINGS INC.	-0.66%	4.26TCr
LONZA GROUP AG	+46.00%	4.18TCr
CELLTRION, INC.	-5.31%	2.9TCr
ICON PUBLIC LIMITED COMPANY	+9.44%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.37%	1.9TCr
BIO-TECHNE CORPORATION	+5.99%	1.28TCr
MEDPACE HOLDINGS, INC.	+27.85%	1.21TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.21%	1.18TCr

Other Biotechnology & Medical Research

Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Biotechnology & Medical Research

Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

Latest news about Vaxxinity, Inc.

Chart Vaxxinity, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research